Polyunsaturated fatty acids, inflammatory processes and inflammatory bowel diseases

Molecular Nutrition and Food Research

Volumn 52, Issue 8, 2008, Pages 885-897

  Calder, Philip C ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

Cytokine; Eicosanoid; Fatty acid; Fish oil; Inflammation

Indexed keywords

ANIMALIA;

ARACHIDONIC ACID; AUTACOID; CYTOKINE; FISH OIL; ICOSANOID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; OMEGA 3 FATTY ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; UNSATURATED FATTY ACID;

ANIMAL; BIOSYNTHESIS; CHEMISTRY; CLINICAL TRIAL; DISEASE MODEL; DRUG ANTAGONISM; ENTERITIS; GENE EXPRESSION REGULATION; GENETICS; HUMAN; INFLAMMATION; METABOLISM; NOMENCLATURE; PHYSIOLOGY; REVIEW;

ANIMALS; ARACHIDONIC ACID; CLINICAL TRIALS AS TOPIC; CYTOKINES; DISEASE MODELS, ANIMAL; EICOSANOIDS; FATTY ACIDS, OMEGA-3; FATTY ACIDS, UNSATURATED; FISH OILS; GENE EXPRESSION REGULATION; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; INFLAMMATORY BOWEL DISEASES; NF-KAPPA B; PPAR GAMMA; TERMINOLOGY AS TOPIC;

EID: 54549108771     PISSN: 16134125     EISSN: 16134133     Source Type: Journal    
DOI: 10.1002/mnfr.200700289     Document Type: Review

References (108)

1. Calder, P. C., Burdge, G. C., Fatty acids, in: Nicolaou, A., Kokotos, G. (Eds.), Bioactive Lipids, The Oily Press, Bridgewater 2004, pp. 1-36.
2. Burdge, G. C., Calder, P. C., Dietary α-linolenic acid and health-related outcomes: A metabolic perspective, Nutr. Res. Rev. 2006, 19, 26-52.
3. British Nutrition Foundation, Briefing Paper: n-3 Fatty Acids and Health, British Nutrition Foundation, London 1999.
4. Lewis, R. A., Austen, K. F., Soberman, R. J., Leukotrienes and other products of the 5-lipoxygenase pathway: Biochemistry and relation to pathobiology in human diseases, N. Eng. J. Med. 1990, 323, 645-655.
5. Tilley, S. L., Coffman, T. M., Koller, B. H., Mixed messages: Modulation of inflammation and immune responses by prostaglandins and thromboxanes, J. Clin. Invest. 2001, 108, 15-23.
6. 2 in protection against mucosal damage, Digestion 2001, 63, 73-80.
7. Nieto, N., Torres, M. I., Rios, A., Gil, A., Dietary polyunsaturated fatty acids improve histological and biochemical alterations in rats with experimental ulcerative colitis, J. Nutr. 2002, 132, 11-19.
8. 4 by colonic mucosa in inflammatory bowel disease, Gastroenterology 1984, 86, 453-460.
9. Empey, L. R., Walker, K., Fedorak, R. N., Fish oil-enriched diet is mucosal protective against acetic acid-induced colitis in rats, Can. J. Physiol. Pharm. 1992, 70, 660-668.
10. Levy, B. D., Clish, C. B., Schmidt, B., Gronert, K., Serhan, C. N., Lipid mediator class switching during acute inflammation: Signals in resolution, Nat. Immunol. 2001, 2, 612-619.
11. Vachier, I., Chanez, P., Bonnans, C., Godard, P., et al., Endogenous anti-inflammatory mediators from arachidonate in human neutrophils, Biochem. Biophys. Res. Commun. 2002, 290, 219-224.
12. Serhan, C. N., Jain, A., Marleau, S., Clish, C., et al., Reduced inflammation and tissue damage in transgenic rabbits overexpressing 15-lipoxygenase and endogenous anti-inflammatory lipid mediators, J. Immunol. 2003, 171, 6856-6865.
13. Gewirtz, A. T., Collier-Hyams, L. S., Young, A. N., Kucharzik, T. et al., Lipoxin A4 analogs attenuate induction of intestinal epithelial proinflammatory gene expression and reduce the severity of dextran sodium sulfate-induced colitis, J. Immunol. 2002, 168, 5260-5267.
14. Lee, T. H., Hoover, R. L., Williams, J. D., Sperling, R. I., et al., Effects of dietary enrichment with eicosapentaenoic acid and docosahexaenoic acid on in vitro neutrophil and monocyte leukotriene generation and neutrophil function, N. Eng. J. Med. 1985, 312, 1217-1224.
15. Endres, S., Ghorbani, R., Kelley, V. E., Georgilis, K., et al., The effect of dietary supplementation with n-3 polyunsaturated fatty acids on the synthesis of interleukin-1 and tumor necrosis factor by mononuclear cells, N. Eng. J. Med. 1989, 320, 265-271.
16. Sperling, R. I., Benincaso, A. I., Knoell, C. T., Larkin, J. K., et al., Dietary ω-3 polyunsaturated fatty acids inhibit phosphoinositide formation and chemotaxis in neutrophils, J. Clin. Invest. 1993, 91, 651-660.
17. Gibney, M. J., Hunter, B., The effects of short- and long-term supplementation with fish oil on the incorporation of n-3 polyunsaturated fatty acids into cells of the immune system in healthy volunteers, Eur. J. Clin. Nutr. 1993, 47, 255-259.
18. Caughey, G. E., Mantzioris, E., Gibson, R. A., Cleland, L. G., James, M. J., The effect on human tumor necrosis factor a and interleukin 1β production of diets enriched in n-3 fatty acids from vegetable oil or fish oil, Am. J. Clin. Nutr. 1996, 63, 116-122.
19. Yaqoob, P., Pala, H. S., Cortina-Borja, M., Newsholme, E. A., Calder, P. C., Encapsulated fish oil enriched in α-tocopherol alters plasma phospholipid and mononuclear cell fatty acid compositions but not mononuclear cell functions, Eur. J. Clin. Invest. 2000, 30, 260-274.
20. Healy, D. A., Wallace, F. A., Miles, E. A., Calder, P. C., Newsholme, P., The effect of low to moderate amounts of dietary fish oil on neutrophil lipid composition and function, Lipids 2000, 35, 763-768.
21. Rees, D., Miles, E. A., Banerjee, T., Wells, S. J., et al., Dose-related effects of eicosapentaenoic acid on innate immune function in healthy humans: A comparison of young and older men, Am. J. Clin. Nutr. 2006, 83, 331-342.
22. Meydani, S. N., Endres, S., Woods, M. M., Goldin, B. R., et al., Oral (n-3) fatty acid supplementation suppresses cytokine production and lymphocyte proliferation: Comparison between young and older women, J. Nutr. 1991, 121, 547-555.
23. 2 production and T-cell function after fish-oil supplementation: Response to antioxidant co-supplementation, Am. J. Clin. Nutr. 2003, 78, 376-382.
24. Kelley, D. S., Taylor, P. C., Nelson, G. J., Schmidt, P. C., et al., Docosahexaenoic acid ingestion inhibits natural killer cell activity and production of inflammatory mediators in young healthy men, Lipids 1999, 34, 317-324.
25. Von Schacky, C., Kiefl, R., Jendraschak, E., Kaminski, W. E., N-3 fatty acids and cysteinyl-leukotriene formation in humans in vitro, ex vivo and in vivo, J. Lab. Clin. Med. 1993, 121, 302-309.
26. 5) derived from eicosapentaenoic acid, Biochem. Biophys. Res. Commun. 1983, 117, 282-288.
27. Lee, T. H., Mencia-Huerta, J. M., Shih, C., Corey, E. J., et al., Characterization and biologic properties of 5,12-dihydroxy derivatives of eicosapentaenoic acid, including leukotriene-B5 and the double lipoxygenase product, J. Biol. Chem. 1984, 259, 2383-2389.
28. Bagga, D., Wang, L., Farias-Eisner, R., Glaspy, J. A., Reddy, S. T., Differential effects of prostaglandin derived from ω-6 and ω-3 polyunsaturated fatty acids on COX-2 expression and IL-6 secretion, Proc. Natl. Acad. Sci. USA 2003, 100, 1751-1756.
29. Calder, P. C., n-3 Polyunsaturated fatty acids, inflammation and immunity: Pouring oil on troubled waters or another fishy tale? Nutr. Res. 2001, 21, 309-341.
30. Calder, P. C., N-3 polyunsaturated fatty acids, inflammation, and inflammatory diseases, Am. J. Clin. Nutr. 2006, 83, 1505S-1519S.
31. Serhan, C. N., Clish, C. B., Brannon, J., Colgan, S. P., et al., Anti-inflammatory lipid signals generated from dietary n-3 fatty acids via cyclooxygenase-2 and transcellular processing: A novel mechanism for NSAID and n-3 PUFA therapeutic actions, J. Physiol. Pharmacol. 2000, 4, 643-654.
32. Serhan, C. N., Clish, C. B., Brannon, J., Colgan, S. P., et al., Novel functional sets of lipid-derived mediators with antinflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2-nonsteroidal antiinflammatory drugs and transcellular processing, J. Exp. Med. 2000, 192, 1197-1204.
33. Serhan, C. N., Hong, S., Gronert, K., Colgan, S. P., et al., Resolvins: A family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter pro-inflammation signals, J. Exp. Med. 2002, 196, 1025-1037.
34. Hong, S., Gronert, K., Devchand, P., Moussignac, R.-L., Serhan, C. N., Novel docosatrienes and 17S-resolvins generated from docosahexaenoic acid in murine brain, human blood and glial cells: Autocoids in anti-inflammation, J. Biol. Chem. 2003, 278, 14677-14687.
35. Marcheselli, V. L., Hong, S., Lukiw, W. J., Hua Tian, X., Novel docosanoids inhibit brain ischemia reperfusion-mediated leukocyte infiltration and pro-inflammatory gene expression, J. Biol. Chem. 2003, 278, 43807-43817.
36. Mukherjee, P. K., Marcheselli, V. L., Serhan, C. N., Bazan, N. G., Neuroprotectin D1: A docosahexaenoic acid-derived docosatriene protects human retinal pigment epithelial cells from oxidative stress, Proc. Natl. Acad. Sci. USA 2004, 101, 8491-8496.
37. Serhan, C. N., Arita, M., Hong, S., Gotlinger, K., Resolvins, docosatrienes, and neuroprotectins, novel omega-3-derived mediators, and their endogenous aspirin-triggered epimers, Lipids 2004, 39, 1125-1132.
38. Serhan, C. N., Novel eicosanoid and docosanoid mediators: Resolvins, docosatrienes, and neuroprotrectins, Curr. Opin. Clin. Nutr. Metab. Care 2005, 8, 115-121.
39. Hudert, C. A., Weylandt, K. H., Lu, Y., Wang, J., et al., Transgenic mice rich in endogenous omega-3 fatty acids are protected from colitis, Proc. Natl. Acad. Sci. USA 2006, 103, 11276-11281.
40. Arita, M., Yoshida, M., Hong, S., Tjonahen, E., et al., Resolvin E1, an endogenous lipid mediator derived from omega-3 eicosapentaenoic acid, protects against 2,4,6-trinitrobenzene sulfonic acid-induced colitis, Proc. Natl. Acad. Sci. USA 2005, 102, 7621-7676.
41. Babcock, T. A., Novak, T., Ong, E., Jho, D. H., et al., Modulation of LPS-stimulated macrophage tumor necrosis factor-α production by ω-3 fatty acid is associated with differential cyclooxygenase-2 protein expression and is independent of interleukin-10, J. Surg. Res. 2002, 107, 135-139.
42. de Caterina, R., Cybulsky, M. I., Clinton, S. K., Gimbrone, M. A., Libby, P., The omega-3 fatty acid docosahexaenoate reduces cytokine-induced expression of proatherogenic and proinflammatory proteins in human endothelial cells, Arterioscler. Thromb. 1994, 14, 1829-1836.
43. Khalfoun, B., Thibault, F., Watier, H., Bardos, P., Lebranchu, Y., Docosahexaenoic and eicosapentaenoic acids inhibit in vitro human endothelial cell production of interleukin-6, Adv. Exp. Biol. Med. 1997, 400, 589-597.
44. Billiar, T., Bankey, P., Svingen, B., Curran, R. D., et al., Fatty acid uptake and Kupffer Cell function: Fish oil alters eicosanoid and monokine production to endotoxin stimulation, Surgery 1988, 104, 343-349.
45. Renier, G., Skamene, E., de Sanctis, J., Radzioch, D., Dietary n-3 polyunsaturated fatty acids prevent the development of atherosclerotic lesions in mice: Modulation of macrophage secretory activities, Arterioscler. Thomb. 1993, 13, 1515-1524.
46. Yaqoob, P., Calder, P. C., Effects of dietary lipid manipulation upon inflammatory mediator production by murine macrophages, Cell. Immunol. 1995, 163, 120-128.
47. Abbate, R., Gori, A. M., Martini, F., Brunelli, T., et al., N-3 PUFA supplementation, monocyte PCA expression and interleukin-6 production, Prost. Leuk. Essent. Fatty Acids 1996, 54, 439-444.
48. Gallai, V., Sarchielli, P., Trequattrini, A., Franceschini, M., et al., Cytokine secretion and eicosanoid production in the peripheral blood mononuclear cells of MS patients undergoing dietary supplementation with n-3 polyunsaturated fatty acids, J. Neuroimmunol. 1993, 56, 143-153.
49. Trebble, T., Arden, N. K., Stroud, M. A., Wootton, S. A., et al., Inhibition of tumour necrosis factor-α and interleukin-6 production by mononuclear cells following dietary fish-oil supplementation in healthy men and response to antioxidant co-supplementation, Br. J. Nutr. 2003, 90, 405-412.
50. Grimble, R. F., Howell, W. M., O'Reilly, G., Turner, S. J., et al., The ability of fish oil to suppress tumor necrosis factor-α production by peripheral blood mononuclear cells in healthy men is associated with polymorphisms in genes that influence tumor necrosis factor-α production, Am. J. Clin. Nutr. 2002, 76, 454-459.
51. Kumar, A., Takada, Y., Boriek, A. M., Aggarwal, B. B., Nuclear factor-kappaB: Its role in health and disease, J. Mol. Med. 2004, 82, 434-448.
52. Sigal, L. H., Basic science for the clinician 39: NF-kappaB-function, activation, control, and consequences, J. Clin. Rheumatol. 2006, 12, 207-211.
53. Perkins, N. D., Integrating cell-signalling pathways with NFkappaB and IKK function, Nat. Rev. Mol. Cell Biol. 2007, 8, 49-62.
54. Zhang, S. Z., Zhao, X. H., Zhang, D. C., Cellular and molecular immunopathogenesis of ulcerative colitis, Cell. Mol. Immunol. 2006, 3, 35-40.
55. Jobin, C., Sartor, R. B., NF-kappaB signaling proteins as therapeutic targets for inflammatory bowel diseases, Inflamm. Bowel Dis. 2000, 6, 206-213.
56. Schottelius, A. J., Baldwin, A. S. Jr., A role for transcription factor NF-kappa B in intestinal inflammation, Int. J. Colorectal Dis. 1999, 14, 18-28.
57. Mansén, A., Guardiola-Diaz, H., Rafter, J., Branting, C., Gustafsson, J. A., Expression of the peroxisome proliferator-activated receptor (PPAR) in the mouse colonic mucosa, Biochem. Biophys. Res. Commun. 1996, 222, 844-851.
58. Desreumaux, P., Ernst, O., Geboes, K., Gambiez, L., et al., Inflammatory alterations in mesenteric adipose tissue in Crohn's disease, Gastroenterology 1999, 117, 73-81.
59. Desreumaux, P., Dubuquoy, L., Nutten, S., Peuchmaur, M. et al., Attenuation of colon inflammation through activators of the retinoid X receptor (RXR)/peroxisome proliferator-activated receptor gamma (PPARgamma) heterodimer. A basis for new therapeutic strategies, J. Exp. Med. 2001, 193, 827-838.
60. Su, C. G., Wen, X., Bailey, S. T., Jiang, W., et al., A novel therapy for colitis utilizing PPAR-gamma ligands to inhibit the epithelial inflammatory response, J. Clin. Invest. 1999, 104, 383-389.
61. Dubuquoy, L., Rousseaux, C., Thuru, X., Peyrin-Biroulet, L., et al., PPARgamma as a new therapeutic target in inflammatory bowel diseases, Gut 2006, 55, 1341-1349.
62. Van den Berghe, W., Vermeulen, L., Delerive, P., De Bosscher, K., Staels, B., Haegeman, G., A paradigm for gene regulation: Inflammation, NF-kappaB and PPAR, Adv. Exp. Med. Biol. 2003, 544, 181-196.
63. Chandrasekar, B., Fernandes, G., Decreased pro-inflammatory cytokines and increased antioxidant enzyme gene expression by ω-3 lipids in murine lupus nephritis, Biochem. Biophys. Res. Commun. 1994, 200, 893-898.
64. Robinson, D. R., Urakaze, M., Huang, R., Taki, H., et al., Dietary marine lipids suppress continuous expression of interleukin-1b gene expression, Lipids 1996, 31, S23-S31.
65. Ross, J. A., Moses, A. G. W., Fearon, K. C. H., The anti-catabolic effects of n-3 fatty acids, Curr. Opin. Clin. Nutr. Metab. Care 1999, 2, 219-226.
66. Lo, C. J., Chiu, K. C., Fu, M., Lo, R., Helton, S., Fish oil decreases macrophage tumor necrosis factor gene transcription by altering the NF kappa B activity, J. Surg. Res. 1999, 82, 216-221.
67. Novak, T. E., Babcock, T. A., Jho, D. H., Helton, W. S., Espat, N. J., NF-kappa B inhibition by omega-3 fatty acids modulates LPS-stimulated macrophage TNF-alpha transcription, Am. J. Physiol. 2003, 284, L84-L89.
68. Zhao, Y., Joshi-Barve, S., Barve, S., Chen, L. H., Eicosapentaenoic acid prevents LPS-induced TNF-alpha expression by preventing NF-kappaB activation, J. Am. Coll. Nutr. 2004, 23, 71-78.
69. Lo, C. J., Chiu, K. C., Fu, M. J., Chu, A., Helton, S., Fish oil modulates macrophage P44/42 mitogen-activated protein kinase activity induced by lipopolysaccharide, J. Parent. Ent. Nutr. 2000, 24, 159-163.
70. Kliewer, S. A., Sundseth, S. S., Jones, S. A., Brown, P. J., et al., Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma, Proc. Natl. Acad. Sci. USA 1997, 94, 4318-4323.
71. Forman, B. M., Chen, J., Evans, R. M., Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta, Proc. Natl. Acad. Sci. USA 1997, 94, 4312-4317.
72. Göttlicher, M., Widmark, E., Li, Q., Gustafsson, J. A., Fatty acids activate a chimera of the clofibric acid-activated receptor and the glucocorticoid receptor, Proc. Natl. Acad. Sci. USA 1992, 89, 4653-4657.
73. Delerive, P., Furman, C., Teissier, E., Fruchart, J., et al., Oxidized phospholipids activate PPARalpha in a phospholipase A2-dependent manner, FEBS Lett. 2000, 471, 34-38.
74. Vilaseca, J., Salas, A., Guarner, F., Rodriguez, R., et al., Dietary fish oil reduces progression of chronic inflammatory lesions in a rat model of granulomatous colitis, Gut 1990, 31, 539-544.
75. Empey, L. R., Jewell, L. D., Garg, M. L., Thomson, A. B., et al., Indomethacin worsens and a leukotriene biosynthesis inhibitor accelerates mucosal healing in rat colitis, Can. J. Physiol. Pharm. 1991, 69, 480-487.
76. Shoda, R., Matsueda, K., Yamato, S., Umeda, N., Therapeutic efficacy of n-3 polyunsaturated fatty acid in experimental Crohn's disease, J. Gastroenterol. 1995, 30, 98-101.
77. Yuceyar, H., Ozutemiz, O., Huseyinov, A., Saruc, M., et al., Is administration of n-3 fatty acids by mucosal enema protective against trinitrobenzene-induced colitis in rats, Prost. Leuk. Essent. Fatty Acids 1999, 61, 339-345.
78. Andoh, A., Tsujikawa, T., Ishizuka, I., Araki, Y., et al., N-3 fatty acid-rich diet prevents early response of interleukin-6 elevation in trinitrobenzene sulfonic acid-induced enteritis, Int. J. Mol. Med. 2003, 12, 721-725.
79. Chapkin, R. S., Davidson, L. A., Ly, L., Weeks, B. R., et al., Immunomodulatory effects of (n-3) fatty acids: Putative link to inflammation and colon cancer, J. Nutr. 2007, 137, 200S-204S.
80. Lorenz, R., Weber, P. C., Szimnau, P., Heldwein, W., et al., Supplementation with n-3 fatty acids from fish oil in chronic inflammatory bowel disease - a randomized, placebo-controlled, double-blind cross-over trial, J. Intern. Med. Suppl. 1989, 731, 225-232.
81. Hillier, K., Jewell, R., Dorrell, L., Smith, C. L., Incorporation of fatty acids from fish oil and olive oil into colonic mucosal lipids and effects upon eicosanoid synthesis in inflammatory bowel disease, Gut 1991, 32, 1151-1155.
82. Hawthorne, A. B., Daneshmend, T. K., Hawkey, C. J., Belluzzi, A., et al., Treatment of ulcerative colitis with fish oil supplementation: A prospective 12 month randomised controlled trial, Gut 1992, 33, 922-928.
83. McCall, T. B., O'Leary, D., Bloomfield, J., O'Morain, C. A., Therapeutic potential of fish oil in the treatment of ulcerative colitis, Aliment. Pharmacol. Ther. 1989, 3, 415-424.
84. Shimizu, T., Fujii, T., Suzuki, R., Igarashi, J., et al., Effects of highly purified eicosapentaenoic acid on erythrocyte fatty acid composition and leukocyte and colonic mucosa leukotriene B4 production in children with ulcerative colitis, Pediat. Gastroenterol. Nutr. 2003, 37, 581-585.
85. Stenson, W. F., Cort, D., Rodgers, J., Burakoff, R., et al., Dietary supplementation with fish oil in ulcerative colitis, Ann. Intern. Med. 1992, 116, 609-614.
86. Trebble, T. M., Arden, N. K., Wootton, S. A., Calder, P. C., et al., Fish oil and antioxidants alter the composition and function of circulating mononuclear cells in Crohn's disease, Am. J. Clin. Nutr. 2004, 80, 1137-1144.
87. Salomon, P., Kornbluth, A. A., Janowitz, H. D., Treatment of ulcerative colitis with fish oil n-3-omega-fatty acid: An open trial, J. Clin. Gastroenterol. 1990, 12, 157-161.
88. Aslan, A., Triadafilopoulos, G., Fish oil fatty acid supplementation in active ulcerative colitis: A double-blind, placebo-controlled, crossover study, Am. J. Gastroenterol. 1992, 87, 432-437.
89. Greenfield, S. M., Green, A. T., Teare, J. P., Jenkins, A. P., et al., A randomized controlled study of evening primrose oil and fish oil in ulcerative colitis, Aliment. Pharmacol. Ther. 1993, 7, 159-166.
90. Belluzzi, A., Brignola, C., Campieri, M., Pera, A., et al., Effect of an enteric-coated fish-oil preparation on relapses in Crohn's disease, N. Eng. J. Med. 1996, 334, 1557-1560.
91. Loeschke, K., Ueberschaer, B., Pietsch, A., Gruber, E., et al., n-3 fatty acids only delay early relapse of ulcerative colitis in remission, Dig. Dis. Sci. 1996, 41, 2087-2094.
92. Lorenz-Meyer, H., Bauer, P., Nicolay, C., Schulz, B., et al., Omega-3 fatty acids and low carbohydrate diet for maintenance of remission in Crohn's disease: A randomized controlled multicenter trial, Scand. J. Gastroenterol. 1996, 31, 778-785.
93. Mantzaris, G., Archavlis, E., Zografos, C., Petraki, K., et al., A prospective, randomized, placebo-controlled study of fish oil in ulcerative colitis, Hellen. J. Gastroenterol. 1996, 9, 138-141.
94. Almallah, Y. Z., Richardson, S., O'Hanrahan, T., Mowat, N. A., et al., Distal procto-colitis, natural cytotoxicity, and essential fatty acids, Am. J. Gastroenterol. 1998, 93, 804-809.
95. Almallah, Y. Z., Ewen, S. W., El-Tahir, A., Mowat, N. A., et al., Distal proctocolitis and n-3 polyunsaturated fatty acids (n-3 PUFAs): The mucosal effect in situ, J. Clin. Immunol. 2000, 20, 68-76.
96. Varghese, T., Coomansingh, D., Clinical response of ulcerative colitis with dietary omega-3 fatty acids: A double-blind randomized study, Br. J. Surg. 2000, 87, 73.
97. Trebble, T. M., Stroud, M. A., Wootton, S. A., Calder, P. C., et al., High dose fish oil and antioxidants in Crohn's disease and the response of bone turnover: A randomised controlled trial, Br. J. Nutr. 2005, 94, 253-261.
98. Middleton, S. J., Naylor, S., Woolner, J., Hunter, J. O., A double-blind, randomized, placebo-controlled trial of essential fatty acid supplementation in the maintenance of remission in ulcerative colitis, Aliment. Pharmacol. Ther. 2002, 16, 1131-1135.
99. Dichi, I., Frenhane, P., Dichi, J. B., Correa, C. R., et al., Comparison of ω-3 fatty acids and sulfasalazine in ulcerative colitis, Nutrition 2000, 16, 87-90.
100. Kirtland, S. J., Prostaglandin E1: A review, Prost. Leuk. Essent. Fatty Acids 1988, 32, 165-174.
101. Fedorak, R. N., Empey, L. R., MacArthur, C., Jewell, L. D., Misoprostol provides a colonic mucosal protective effect during acetic acid-induced colitis in rats, Gastroenterol. 1990, 98, 615-625.
102. Yamada, T., Specian, R. D., Granger, D. N., Gaginella, T. S., Grisham, M. B., Misoprostol attenuates acetic acid-induced increases in mucosal permeability and inflammation: Role of blood flow, Am. J. Physiol. 1991, 261, G332-G339.
103. Torsher, K. J., Empey, L. R., Fedorak, R. N., Misoprostol therapy following trinitrobenzene sulfonic acid-induced colitis accelerates healing, Prost. Leuk. Essent. Fatty Acids 1992, 45, 275-281.
104. Yamada, T., Fujimoto, K., Tso, P., Fujimoto, T., et al., Misoprostol accelerates colonic mucosal repair in acetic acid-induced colitis, J. Pharmacol. Exp. Ther. 1992, 260, 313-318.
105. Rodgers, J. B., N-3 fatty acids in the treatment of ulcerative colitis, in: Kremer, J. M. (Ed.), Medicinal Fatty Acids in Inflammation, Birkhauser Verlag, Basel 1998, pp. 103-109.
106. Belluzzi, A., N-3 fatty acids for the treatment of inflammatory bowel diseases, Proc. Nutr. Soc. 2002, 61, 391-395.
107. Belluzzi, A., Polyunsaturated fatty acids and inflammatory bowel disease, Am. J. Clin. Nutr. 2000, 71, 339S-342S.
108. MacLean, C. H., Mojica, W. A., Morton, S. C., Pencharz, J., et al., Effects of omega-3 fatty acids on inflammatory bowel disease, rheumatoid arthritis, renal disease, systemic lupus erythematosus, and osteoporosis, Evidence Report/Technical Assessment No. 89. AHRQ Publication No. 04-E012-2, Agency for Healthcare Research and Quality, Rockville 2004.